Clinical Trial Update: Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a recombinant quadrivalent influenza vaccine to a marketed quadrivalent in children aged 3 to 17 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Human

Drugs mentioned

• marketed quadrivalent inactivated influenza vaccine
• recombinant quadrivalent influenza vaccine

Snippet

Sponsor: Laboratorios Liomont | Conditions: Influenza, Human | Phase 3 | Status: COMPLETED